Strs Ohio Buys 18,110 Shares of Celgene Co. (CELG)

Strs Ohio increased its stake in Celgene Co. (NASDAQ:CELG) by 2.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 908,586 shares of the biopharmaceutical company’s stock after purchasing an additional 18,110 shares during the quarter. Strs Ohio owned approximately 0.12% of Celgene worth $132,490,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the stock. Thompson Davis & CO. Inc. increased its stake in Celgene by 5.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 43 shares in the last quarter. Arcadia Investment Management Corp MI increased its stake in Celgene by 118.7% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 400 shares in the last quarter. Motco increased its stake in Celgene by 19.3% in the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 159 shares in the last quarter. Penserra Capital Management LLC purchased a new stake in Celgene in the 2nd quarter worth $129,000. Finally, Balentine LLC increased its stake in Celgene by 83.5% in the 2nd quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 481 shares in the last quarter. 79.84% of the stock is currently owned by institutional investors.

Celgene Co. (NASDAQ:CELG) opened at $107.88 on Friday. The company has a market capitalization of $84,940.00, a PE ratio of 16.73, a P/E/G ratio of 0.83 and a beta of 1.77. Celgene Co. has a 12-month low of $94.55 and a 12-month high of $147.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.

Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm’s revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the business posted $1.58 earnings per share. analysts expect that Celgene Co. will post 6.68 EPS for the current year.

A number of equities research analysts have issued reports on the company. UBS lowered Celgene from a “strong-buy” rating to a “market perform” rating and set a $160.00 price target for the company. in a research note on Thursday, October 26th. BMO Capital Markets cut their price objective on Celgene from $163.00 to $148.00 and set an “outperform” rating for the company in a research report on Friday, October 27th. Jefferies Group restated a “buy” rating and set a $160.00 price objective on shares of Celgene in a research report on Friday, September 15th. BTIG Research restated a “neutral” rating on shares of Celgene in a research report on Tuesday, September 5th. Finally, Robert W. Baird lowered Celgene from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $162.00 to $136.00 in a research report on Friday, October 20th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the stock. Celgene currently has a consensus rating of “Buy” and an average price target of $136.21.

In related news, insider Terrie Curran sold 1,727 shares of Celgene stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now owns 3,925 shares in the company, valued at $564,768.25. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.95% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was posted by Community Financial News and is owned by of Community Financial News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.com-unik.info/2017/12/22/strs-ohio-buys-18110-shares-of-celgene-co-celg.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

What are top analysts saying about Celgene? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit